Trial Profile
A Study to Evaluate Whether mRNA Expression of REV3, BRCA1, RAP80, TS and AEG1 Genes Either Alone or in Combination Improve the Outcome in Cisplatin plus Pemetrexed Treated Non Small Cell Lung Cancer (NSCLC) Patients
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 22 Dec 2015
Price :
$35
*
At a glance
- Drugs Cisplatin (Primary) ; Pemetrexed (Primary)
- Indications Non-small cell lung cancer
- Focus Pharmacodynamics; Therapeutic Use
- 22 Dec 2015 New trial record